Development of the Predictor hERG Fluorescence Polarization Assay Using a Membrane Protein Enrichment Approach
- 1 April 2008
- journal article
- research article
- Published by Mary Ann Liebert Inc in ASSAY and Drug Development Technologies
- Vol. 6 (2), 213-223
- https://doi.org/10.1089/adt.2008.137
Abstract
The life-threatening consequences of acquired, or drug-induced, long QT syndrome due to block of the human ether-a-go-go-related gene (hERG) channel are well appreciated and have been the cause of several drugs being removed from the market in recent years because of patient death. In the last decade, the propensity for block of the hERG channel by a diverse and expanding set of compounds has led to the requirement that all new drugs be tested for hERG channel block in a functional patch-clamp assay. Because of the need to identify potential hERG blockers early in the discovery process, radiometric hERG binding assays are preferred over patch-clamp assays for compound triage, because of relative advantages in speed and cost. Even so, these radiometric binding assays are laborious and require dedicated instrumentation and infrastructure to cope with the regulatory and safety issues associated with the use of radiation. To overcome these limitations, we developed a homogeneous, fluorescence polarization-based assay to identify and characterize the affinity of small molecules for the hERG channel and have demonstrated tight correlation with data obtained from either radioligand binding or patch-clamp assays. Key to the development of this assay was a cell line that expressed highly elevated levels of hERG protein, which was generated by coupling expression of the hERG channel to that of a selectable cell surface marker. A high-expressing clone was isolated by flow cytometry and used to generate membrane preparations that contained >50-fold the typical density of hERG channels measured by [3H]astemizole binding. This strategy enabled the Predictor™ (Invitrogen, Carlsbad, CA) hERG fluorescence polarization assay and should be useful in the development of other fluorescence polarization-based assays that use membrane proteins.Keywords
This publication has 29 references indexed in Scilit:
- Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks™ HTJournal of Pharmacological and Toxicological Methods, 2006
- hERG potassium channels and cardiac arrhythmiaNature, 2006
- Differential Inhibition of Inducible T Cell Cytokine Secretion by Potent Iron ChelatorsSLAS Discovery, 2005
- Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel BlockersJournal of Medicinal Chemistry, 2002
- ICH Topic: The draft ICH S7B step 2: Note for guidance on safety pharmacology studies for human pharmaceuticalsFundamental & Clinical Pharmacology, 2002
- The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of CardiologyPublished by Oxford University Press (OUP) ,2000
- HERG, a Human Inward Rectifier in the Voltage-Gated Potassium Channel FamilyScience, 1995
- A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channelCell, 1995
- A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndromeCell, 1995
- A family of potassium channel genes related to eag in Drosophila and mammals.Proceedings of the National Academy of Sciences of the United States of America, 1994